Selank: The Anxiolytic Peptide With a 40-Year Russian Research Trail

What Is Selank?

Selank is a synthetic heptapeptide — seven amino acids in sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was engineered at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analog of tuftsin, a naturally occurring tetrapeptide fragment of immunoglobulin G that the body produces endogenously.

The original tuftsin molecule (Thr-Lys-Pro-Arg) degrades rapidly in biological fluids. Researchers extended the sequence with Pro-Gly-Pro at the C-terminus to slow enzymatic breakdown and extend plasma half-life — creating what became Selank. The compound earned regulatory approval in Russia as a treatment for generalized anxiety disorder (GAD) and is administered as an intranasal spray. Outside Russia, it has no approved medical use but has attracted significant research interest for its anxiolytic, nootropic, and immunomodulatory properties.

Mechanism: How Selank Works

The core anxiolytic mechanism involves positive allosteric modulation of GABA-A receptors — the same general pathway targeted by benzodiazepines. This is meaningful because it places Selank in a mechanistic category that practitioners already understand, while the clinical profile looks quite different from classical benzodiazepines.

Gene expression studies in rat frontal cortex found that intranasal Selank alters the expression of multiple genes involved in GABAergic neurotransmission, including subunits of the GABA-A receptor (Gabra1, Gabrb1/3, Gabbr1), transporters (Slc6a1, Slc32a1), and related enzymes. The pattern of changes substantially overlaps with those induced by GABA itself — consistent with allosteric potentiation of the receptor rather than direct agonism at the benzodiazepine binding site.

Additionally, Selank appears to inhibit enzymes that degrade enkephalins — endogenous opioid peptides with anxiolytic properties — providing a secondary mechanism distinct from GABAergic modulation. The compound also upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus, which may contribute to its nootropic profile and cognitive-sparing effects.

The 2008 Clinical Trial

The most cited clinical evidence comes from a 2008 randomized controlled trial by Zozulia et al. involving 62 patients with GAD and neurasthenia — 30 assigned to Selank and 32 to medazepam (a reference benzodiazepine). Both groups received treatment for 14 days.

The results showed comparable reductions in anxiety across psychometric scales including the Hamilton Anxiety Rating Scale and the Zung Self-Rating Anxiety Scale. However, the profiles differed meaningfully:

• Selank produced anxiolytic effects without sedation, amnesia, or motor impairment
• Selank showed antiasthenic effects — reducing fatigue and mental fog — where medazepam did not
• No withdrawal symptoms or dependence signals were observed in the Selank group
• The investigators noted a correlation between changes in serum leu-enkephalin levels and symptom improvement, supporting the enkephalin-related mechanism

This is a small single trial with limitations typical of early-stage pharmaceutical research — modest sample size, conducted in Russia, published in a Russian-language journal. Independent replication in larger Western-designed RCTs has not yet been done. That is a genuine limitation practitioners should note.

Immunomodulatory Properties

Selank’s relationship to tuftsin gives it an immunological dimension that most anxiolytic compounds don’t have. Tuftsin itself is an endogenous immunostimulatory peptide; the Selank analog carries forward some of that activity in modified form.

A 2008 human study (Uchakina et al.) examined Selank’s effects on cytokine profiles in patients with anxiety-asthenic disorders over 14 days. Researchers found that Selank altered the Th1/Th2 cytokine balance and suppressed IL-6 gene expression in peripheral blood cells taken from affected patients. Animal studies have shown that Selank normalizes pro-inflammatory cytokines — including IL-1β, IL-6, and TNF-α — when elevated by social stress.

Separately, Selank has been shown to induce interferon-alpha gene expression, suggesting modest antiviral immune activity alongside its CNS effects.

The immune findings are early-stage and largely preclinical, but they point toward Selank having broader biological activity than a conventional anxiolytic — which is relevant to clinicians thinking about patients whose anxiety and immune function are both dysregulated.

Regulatory Status in the United States (2026)

Selank has never been an FDA-approved drug in the United States. Its compounding status has shifted considerably:

In late 2023, the FDA placed Selank (along with Semax, MOTS-c, and others) on the Category 2 bulk substances list — meaning potential significant safety concerns had been identified, effectively restricting 503A compounding pharmacy use. The cited concerns included immunogenicity and aggregation risks at certain administration routes.

In April 2026, the FDA removed Selank from active Category 2 enforcement priority. It now sits in a Category 1 “under evaluation” posture, meaning compounding pharmacies can generally continue while the formal PCAC review process proceeds. This is not FDA approval, not placement on the affirmative 503A bulks list, and not a guarantee of long-term compounding eligibility. The landscape will continue to evolve.

For practitioners: ordering or recommending compounded Selank today is operating in a gray area that carries regulatory risk proportional to enforcement posture at any given time. The July 2026 PCAC meeting and subsequent reviews will be the ones to watch.

What the Evidence Supports — and What It Doesn’t

The evidence reasonably supports:

• Anxiolytic effects in GAD comparable to benzodiazepines, without sedation or dependence
• BDNF upregulation in the hippocampus with potential neuroprotective implications
• Immunomodulatory activity consistent with its tuftsin-derived structure
• Favorable short-term safety profile in the available trials

What the evidence does not yet support to a Western regulatory standard:

• Large-scale, independently replicated RCTs
• Long-term safety data
• Cognitive enhancement claims beyond secondary observations in anxiety trials
• Approved use in any condition outside Russia

The research base is legitimate and indexed on PubMed, but it is narrower and more geographically concentrated than the evidence behind peptides with decades of Western clinical development. That is a meaningful distinction for clinical decision-making.

The Broader Picture

Selank occupies an interesting position in the peptide research space: it is one of the few compounds in this class that carries formal regulatory approval in any jurisdiction (Russia), has a defined mechanism consistent with understood pharmacology, and has been studied in actual human clinical trials. For practitioners navigating patient interest in nootropic and anxiolytic peptides, it represents a more evidence-grounded option than many alternatives.

The translation gap — from Russian-language trials to mainstream Western clinical literature — is real. But the mechanistic logic is solid, the safety signals in available data are favorable, and the regulatory picture in the U.S. is currently less restrictive than it was a year ago.

For more on peptide sourcing transparency and how to evaluate vendor quality, see our sourcing transparency page and the peptide COA guide. For context on the broader 503A/503B regulatory environment, see our compounding landscape overview.

This article is for educational purposes only and does not constitute medical advice. Selank is not an FDA-approved drug in the United States. Consult a licensed healthcare provider before using any peptide therapy.